ヒトマイクロバイオーム市場：疾患別、技術別、製品別、治療領域別、用途別-2025-2030年の世界予測

ヒトマイクロバイオーム市場は、2023年に15億8,000万米ドルと評価され、2024年には19億6,000万米ドルに達すると予測され、CAGR 23.90％で成長し、2030年には71億1,000万米ドルになると予測されています。

ヒトマイクロバイオームは、細菌、ウイルス、真菌、その他の微生物を含む、人体上および人体内に存在する微生物の巨大なコンソーシアムを指します。その定義は、消化、免疫、さらには精神的な幸福にまで影響を及ぼす、人間の健康の重要な要素にまで及ぶ。ヒトマイクロバイオームを探求する必要性は、健康治療や疾病予防に革命をもたらす可能性があるからです。用途は個別化医療からプロバイオティクスまで多岐にわたり、ヘルスケア、製薬、バイオテクノロジー業界の多様な最終用途を反映しています。市場の洞察によれば、研究投資の増加と微生物に関連した健康上の利点に対する消費者の意識が、市場の堅調な成長を後押ししています。成長に影響を与える主な要因としては、ゲノム配列決定の技術的発展、革新的な治療法を開発するためのバイオテクノロジー企業と研究機関の協力関係の拡大などが挙げられます。特に、標的を絞ったプロバイオティクスやプレバイオティクス、マイクロバイオーム診断、炎症性腸疾患や糖尿病などの疾患に対する治療ソリューションの開発において、ビジネスチャンスが急速に生まれつつあります。これらを活用するために、企業はダイナミックなパートナーシップと継続的な研究開発に注力し、マイクロバイオーム製品の主流用途への統合を推進すべきです。しかし、高い開発コスト、規制上の課題、マイクロバイオームの動態を理解することの複雑さといった制約が、成長の足かせとなっています。ゲノムデータに関するプライバシーの問題も障壁となっています。これらの課題に対処するには、透明性の高い規制の道筋と、データの正確性とプライバシー保護を強化するための協力体制が必要です。技術革新と研究に最適な分野としては、治療目的のための合成工学的マイクロバイオームや、宿主と微生物の相互作用をより深く理解するためのメタゲノム解析技術の進歩が挙げられます。市場は急速に発展しており、各社がマイクロバイオームデータを健康状態の改善に役立てようと努力しているため、競争的でありながら協調的であることが特徴です。したがって、企業はこの有望な領域で事業成長を達成するために、しっかりとした調査、規制への認識、市場の多様化を組み合わせた戦略的アプローチを採用すべきです。

市場力学：急速に進化するヒトマイクロバイオーム市場の主要市場インサイトを公開

ヒトマイクロバイオーム市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ヒトマイクロバイオーム療法開発への注目の高まり
  • 創薬、病気の早期発見、診断のためのヒトマイクロバイオーム
  • プロバイオティクスと乳児栄養におけるマイクロバイオームに対する需要の増加
• 市場抑制要因
  • マイクロバイオーム治療薬に関する限られた専門知識と安全性の問題
• 市場機会
  • 共同研究および研究投資の増加による成長機会の創出
  • 新規ヒトマイクロバイオーム治療薬の開発
• 市場の課題
  • 細菌種数の把握の限界とヒトマイクロバイオームに基づく医薬品の不確実性

ポーターの5つの力：ヒトマイクロバイオーム市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヒトマイクロバイオーム市場における外部からの影響の把握

外部マクロ環境要因は、ヒトマイクロバイオーム市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ヒトマイクロバイオーム市場における競合情勢の把握

ヒトマイクロバイオーム市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスヒトマイクロバイオーム市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヒトマイクロバイオーム市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ヒトマイクロバイオーム療法の開発への重点化
    • 創薬、早期疾患検出、診断のためのヒトマイクロバイオーム
    • プロバイオティクスと乳児栄養におけるマイクロバイオームの需要増加
  • 抑制要因
    • マイクロバイオーム治療に関する専門知識の不足と安全性の問題
  • 機会
    • 成長機会を創出するためのコラボレーションと調査投資の拡大
    • 新規治療薬の開発
  • 課題
    • 細菌種の数の理解における限界とヒトマイクロバイオームに基づく医薬品の不確実性
• 市場セグメンテーション分析
  • 技術：人体の分子因子とプロセスを調査するための16s rRNAシーケンシングとオミックス技術の最近の進歩
  • 応用：さまざまな健康状態に対応するために、ヘルスケア診断および治療におけるヒトマイクロバイオームの採用が増加しています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ
  • 知的財産の情勢

第6章 ヒトマイクロバイオーム市場：疾患別

• 急性下痢
• 自己免疫疾患
• がん
• 糖尿病
• 精神障害
• 肥満

第7章 ヒトマイクロバイオーム市場：技術別

• 16s rRNAシーケンシング
• 細胞培養技術
• 計算ツール
• 高スループット技術
• メタゲノムシーケンシング
• オミックス技術

第8章 ヒトマイクロバイオーム市場：製品別

• 診断装置
• 薬物
• 食品
• プレバイオティクスとプロバイオティクス

第9章 ヒトマイクロバイオーム市場治療領域別

• 胃腸障害
• 代謝障害
• 皮膚疾患
• 女性の健康

第10章 ヒトマイクロバイオーム市場：用途別

• 診断
• 治療薬

第11章 南北アメリカのヒトマイクロバイオーム市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のヒトマイクロバイオーム市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのヒトマイクロバイオーム市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Clinical MicrobiomicsがCosmosIDとの合併を発表
  • ネスレ、健康とウェルビーイング製品でAPC Microbiomeと提携
  • ワシントン大学医学部がマイクロバイオーム研究のための新センターを設立

企業一覧

• Merck KGaA
• Theriva Biologics, Inc.
• BiomeSense, Inc.
• Metabiomics Corporation
• Exeliom Biosciences SAS
• Ferring B.V.
• Evelo Biosciences, Inc.
• Locus Biosciences, Inc.
• Intralytix, Inc.
• Seres Therapeutics, Inc.
• DuPont de Nemours, Inc.
• Invivo Healthcare
• Vedanta Biosciences, Inc.
• Astarte Medical Partners, Inc
• Synlogic, Inc.
• Finch Therapeutics Group, Inc.
• Rebiotix Inc.
• Osel Inc.
• Second Genome, Inc.
• Enterome Bioscience
• Axial Therapeutics, Inc.
• Viome Life Sciences, Inc.
• Yakult Honsha Co., Ltd.
• Azitra
• Illumina, Inc.
• BiomX Ltd.
• AOBiome, LLC

LIST OF FIGURES

• FIGURE 1. HUMAN MICROBIOME MARKET RESEARCH PROCESS
• FIGURE 2. HUMAN MICROBIOME MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HUMAN MICROBIOME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HUMAN MICROBIOME MARKET DYNAMICS
• TABLE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ACUTE DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MENTAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPUTATIONAL TOOLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HIGH-THROUGHPUT TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METAGENOMIC SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY FOODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTIC & PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 51. CANADA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. CANADA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. CANADA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 54. CANADA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. CHINA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. CHINA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. CHINA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. CHINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 81. CHINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. INDIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 83. INDIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. INDIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. INDIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 86. INDIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 96. JAPAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 101. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 106. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 111. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 121. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 126. THAILAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 131. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 142. DENMARK HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 147. EGYPT HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 152. FINLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 157. FRANCE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 162. GERMANY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 167. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. ITALY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 169. ITALY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. ITALY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 171. ITALY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 172. ITALY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 177. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 182. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 187. NORWAY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. POLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 189. POLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. POLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. POLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 192. POLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. QATAR HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 194. QATAR HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 195. QATAR HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 196. QATAR HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 197. QATAR HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 202. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 207. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 217. SPAIN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 222. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 227. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 232. TURKEY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 237. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 242. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 243. HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 244. HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2023

The Human Microbiome Market was valued at USD 1.58 billion in 2023, expected to reach USD 1.96 billion in 2024, and is projected to grow at a CAGR of 23.90%, to USD 7.11 billion by 2030.

The human microbiome refers to the vast consortium of microorganisms residing on and within the human body, encompassing bacteria, viruses, fungi, and other microbes. Its definition extends to a critical component of human health, influencing digestion, immunity, and even mental well-being. The necessity of exploring the human microbiome is driven by its potential to revolutionize health treatments and disease prevention. Applications span from personalized medicine to probiotics, reflecting diverse end-use arenas in healthcare, pharmaceuticals, and biotechnology industries. The market insights suggest robust growth fueled by increased research investment and consumer awareness of microbiome-related health benefits. Key influencing growth factors include technological advancements in genomic sequencing and growing collaborations between biotech firms and research institutions to develop innovative therapies. Opportunities are emerging rapidly, particularly in developing targeted probiotics and prebiotics, microbiome diagnostics, and therapeutic solutions for diseases like inflammatory bowel disease and diabetes. To capitalize on these, businesses should focus on dynamic partnerships and continuous R&D to drive microbiome-product integration into mainstream applications. However, limitations such as high development costs, regulatory challenges, and the complexity of understanding microbiome dynamics tempers growth. Privacy concerns regarding genomic data also pose barriers. Addressing these challenges requires transparent regulatory pathways and collaborations to enhance data accuracy and privacy protections. The best areas for innovation and research include synthetically engineered microbiomes for therapeutic purposes and advancing techniques in metagenomic analysis to better understand host-microbe interactions. The market is rapidly evolving, marked by a competitive yet collaborative nature as companies strive to harness microbiome data for improving health outcomes. Thus, firms should adopt a strategic approach combining robust research, regulatory awareness, and market diversification to achieve business growth in this promising domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Microbiome Market

The Human Microbiome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased Focus on Development of Human Microbiome Therapy
  • Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
  • Increasing Demand for Microbiome in Probiotics and Infant Nutrition
• Market Restraints
  • Limited Expertise and Safety Issue related to Microbiome Therapeutics
• Market Opportunities
  • Increasing Collaborations and Research Investments to Create Growth Opportunities
  • Development of Novel Human Microbiome Therapeutic Products
• Market Challenges
  • Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Human Microbiome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Microbiome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Microbiome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Microbiome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Microbiome Market

A detailed market share analysis in the Human Microbiome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Microbiome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Microbiome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Human Microbiome Market, highlighting leading vendors and their innovative profiles. These include Merck KGaA, Theriva Biologics, Inc., BiomeSense, Inc., Metabiomics Corporation, Exeliom Biosciences SAS, Ferring B.V., Evelo Biosciences, Inc., Locus Biosciences, Inc., Intralytix, Inc., Seres Therapeutics, Inc., DuPont de Nemours, Inc., Invivo Healthcare, Vedanta Biosciences, Inc., Astarte Medical Partners, Inc, Synlogic, Inc., Finch Therapeutics Group, Inc., Rebiotix Inc., Osel Inc., Second Genome, Inc., Enterome Bioscience, Axial Therapeutics, Inc., Viome Life Sciences, Inc., Yakult Honsha Co., Ltd., Azitra, Illumina, Inc., BiomX Ltd., and AOBiome, LLC.

Market Segmentation & Coverage

This research report categorizes the Human Microbiome Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease, market is studied across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity.
• Based on Technology, market is studied across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology.
• Based on Product, market is studied across Diagnostic Devices, Drugs, Foods, and Prebiotic & Probiotics.
• Based on Therapeutic Area, market is studied across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women's Health.
• Based on Application, market is studied across Diagnostics and Therapeutics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased Focus on Development of Human Microbiome Therapy
    • 5.1.1.2. Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
    • 5.1.1.3. Increasing Demand for Microbiome in Probiotics and Infant Nutrition
  • 5.1.2. Restraints
    • 5.1.2.1. Limited Expertise and Safety Issue related to Microbiome Therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Collaborations and Research Investments to Create Growth Opportunities
    • 5.1.3.2. Development of Novel Human Microbiome Therapeutic Products
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Recent advancements in 16s rRNA sequencing and omics technology to investigate molecular factors and processes in human body
  • 5.2.2. Application: The increasing adoption of the human microbiome in healthcare diagnostics and therapeutics to cater to various health conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. Intellectual Property Landscape

6. Human Microbiome Market, by Disease

• 6.1. Introduction
• 6.2. Acute Diarrhea
• 6.3. Autoimmune Disorders
• 6.4. Cancer
• 6.5. Diabetes
• 6.6. Mental Disorders
• 6.7. Obesity

7. Human Microbiome Market, by Technology

• 7.1. Introduction
• 7.2. 16s rRNA Sequencing
• 7.3. Cell Culture Technology
• 7.4. Computational Tools
• 7.5. High-Throughput Technology
• 7.6. Metagenomic Sequencing
• 7.7. Omics Technology

8. Human Microbiome Market, by Product

• 8.1. Introduction
• 8.2. Diagnostic Devices
• 8.3. Drugs
• 8.4. Foods
• 8.5. Prebiotic & Probiotics

9. Human Microbiome Market, by Therapeutic Area

• 9.1. Introduction
• 9.2. Gastrointestinal Disorders
• 9.3. Metabolic Disorders
• 9.4. Skin Disorders
• 9.5. Women's Health

10. Human Microbiome Market, by Application

• 10.1. Introduction
• 10.2. Diagnostics
• 10.3. Therapeutics

11. Americas Human Microbiome Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Human Microbiome Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Human Microbiome Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Clinical Microbiomics Announces Merger with CosmosID
  • 14.3.2. Nestle Partners APC Microbiome on Health and Wellbeing Products
  • 14.3.3. UW Medicine Launches a New Center to Study Microbiomes

Companies Mentioned

• 1. Merck KGaA
• 2. Theriva Biologics, Inc.
• 3. BiomeSense, Inc.
• 4. Metabiomics Corporation
• 5. Exeliom Biosciences SAS
• 6. Ferring B.V.
• 7. Evelo Biosciences, Inc.
• 8. Locus Biosciences, Inc.
• 9. Intralytix, Inc.
• 10. Seres Therapeutics, Inc.
• 11. DuPont de Nemours, Inc.
• 12. Invivo Healthcare
• 13. Vedanta Biosciences, Inc.
• 14. Astarte Medical Partners, Inc
• 15. Synlogic, Inc.
• 16. Finch Therapeutics Group, Inc.
• 17. Rebiotix Inc.
• 18. Osel Inc.
• 19. Second Genome, Inc.
• 20. Enterome Bioscience
• 21. Axial Therapeutics, Inc.
• 22. Viome Life Sciences, Inc.
• 23. Yakult Honsha Co., Ltd.
• 24. Azitra
• 25. Illumina, Inc.
• 26. BiomX Ltd.
• 27. AOBiome, LLC